ArticleJournal of diabetes and metabolic disorders2024
NF-kappa B signaling pathway is associated with metformin resistance in type 2 diabetes patients.
Article in Journal of diabetes and metabolic disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CCL4L2 is a potential biomarker for differentiating central and peripheral vertigo.Frontiers in integrative neuroscience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Metformin is an essential medicine that is most widely prescribed frontline for the treatment of Type 2 diabetes (T2D). Metformin upgraded glycemic control in T2D patients without hypoglycemic effects in patients. This assessment aims to understand molecular mechanism mechanisms in non-responder patients to metformin. Methods: Gene expression profiles of responder and non-responder T2D patients to metformin are extracted from Gene Expression Omnibus (GEO) and are evaluated by the GEO2R program to find the significant differentially expressed genes (DEGs). The significant DEGs have been studied via action map gene ontology analyses. Results: Results indicate that 563 significant DEGs discriminate non-responders from responder groups. "NF-kappa B signaling pathway" and 11 DEGs including BIRC3, CCL4L2, CXCL2, ICAM1, LYN, MYD88, RELA, SYK, TLR4, TNFAIP3, and TRIM25 were pointed out as core of drug resistance. Conclusion: It can be concluded that there are differences between gene expression analysis, the response of diabetic patients to metformin. Results indicate that dysregulation of the "NF-kappa B signaling pathway" and TNFAIP3, BIRC3, RELA, MYD88, TLR4, and ICAM1 is associated with drug resistance in T2D patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.